Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ab&B Bio-Tech Partners with Walvax for Overseas Push – First China-Approved Trivalent Subunit Influenza Vaccine Targets Global Markets

Fineline Cube Mar 16, 2026
Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Fineline Cube Mar 13, 2026
Company Deals

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

Fineline Cube Mar 13, 2026
Company Deals

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications

Fineline Cube Mar 13, 2026
Company Deals

Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD

Fineline Cube Mar 13, 2026
Policy / Regulatory

China’s Basic Medical Insurance Covers 1.33 Billion in 2025 – NHSA Reports RMB 3.6 Trillion Fund Inflows, 114 New Drugs Added to NRDL

Fineline Cube Mar 16, 2026
Company Drug

CMS Secures NMPA Approval for Desidustat – First Domestic HIF-PHI for Non-Dialysis CKD Anemia Enters China Market

Fineline Cube Mar 16, 2026
Company Drug

Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine

Fineline Cube Mar 16, 2026
Company Deals

F-star Therapeutics and Sino Biopharmaceutical Face Delays in Proposed Acquisition

Fineline Cube Dec 30, 2022

UK-based biotech F-star Therapeutics (NASDAQ: FSTX) released an SEC filing indicating that the proposed acquisition...

Company Drug

CSPC’s ALMB-0168 Receives NMPA Approval for Osteoarthritis Clinical Study

Fineline Cube Dec 30, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...

Company Drug

RemeGen’s RC108 Receives FDA Go-Ahead for Phase I Clinical Study

Fineline Cube Dec 30, 2022

China-based biopharma RemeGen Ltd (HKG: 9995) has announced receiving approval from the US FDA to...

Company Drug

Simcere Receives NMPA Clearance for SIM0348 Clinical Study

Fineline Cube Dec 30, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...

Company Deals

Skynor Medical Raises RMB 100 Million in Financing Round for Market Expansion

Fineline Cube Dec 30, 2022

Skynor Medical, a Shanghai-based manufacturer of nerve and peripheral blood vessel implantation and interventional devices,...

Company Deals

Sichuan Kelun Completes RMB 1.5 Billion Financing Round for Kelun-Biotech

Fineline Cube Dec 30, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced the completion of a financing...

Company Drug

Everest Medicines’ Nefecon Receives Priority Review Recommendation from CDE

Fineline Cube Dec 30, 2022

China-based Everest Medicines (HKG: 1952) has announced that the Center for Drug Evaluation (CDE) of...

Company Drug

BrightGene Receives NMPA Approval for BGM0504 Clinical Trial

Fineline Cube Dec 30, 2022

China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has announced that it has received clinical...

Drug

Anhui Anke Biotechnology Receives NMPA Approval for AK2017 Clinical Study

Fineline Cube Dec 30, 2022

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced receiving approval from the...

Company Drug

AstraZeneca’s Nexium Approved by NMPA for Adolescent GERD Treatment

Fineline Cube Dec 30, 2022

UK-based pharmaceutical major AstraZeneca (NASDAQ: AZN) has announced receiving market approval from the National Medical...

Company Deals

Sino Biopharmaceutical Secures Rights to Shionogi’s COVID-19 Therapy Ensitrelvir

Fineline Cube Dec 30, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia Tai Tianqing...

Company Deals

Shenzhen Core Medical Raises ‘Hundreds of Millions’ in Series C Financing

Fineline Cube Dec 30, 2022

Shenzhen-based heart failure mechanical circulatory support solutions provider, Shenzhen Core Medical Technology Co., Ltd, has...

Company

Sinovac Reports H1 2022 Financials Amid COVID-19 Vaccine Demand Decline

Fineline Cube Dec 30, 2022

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has released its financial report for the first half...

Company Drug

Junshi Biosciences’ JT001 (VV116) Shows Non-Inferiority to Paxlovid in COVID-19 Trial

Fineline Cube Dec 29, 2022

The results of a Phase III clinical study for China-based Junshi Biosciences’ (HKG: 1877, SHA:...

Company Drug Legal / IP

Hainan Shuangcheng Files Paragraph IV Patent Declaration for Paclitaxel, Albumin-Bound

Fineline Cube Dec 29, 2022

China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has announced a Paragraph IV patent declaration...

Company Drug

Grand Pharma’s COVID-19 Therapy GS221 Shows Promising Safety Profile

Fineline Cube Dec 29, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its clinical study for the...

Company Drug

Fosun Pharma Launches Online Registration for BioNTech COVID-19 Vaccine in Hong Kong

Fineline Cube Dec 29, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced a new initiative...

Company Drug

Immunotech Biopharm’s CAR-T-19-D2 IND Filing Accepted by NMPA

Fineline Cube Dec 29, 2022

China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced that...

Company Medical Device

Acotec Scientific Holdings Receives NMPA Approvals for YAN and P-Conic Balloon

Fineline Cube Dec 29, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving market approvals from the National...

Company Drug

CanSino Biologics Updates Data from COVID-19 Vaccine Clinical Studies

Fineline Cube Dec 29, 2022

China-based CanSino Biologics (HKG: 6185) has provided data updates from three clinical studies for its...

Posts pagination

1 … 549 550 551 … 635

Recent updates

  • Ab&B Bio-Tech Partners with Walvax for Overseas Push – First China-Approved Trivalent Subunit Influenza Vaccine Targets Global Markets
  • CMS Secures NMPA Approval for Desidustat – First Domestic HIF-PHI for Non-Dialysis CKD Anemia Enters China Market
  • Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine
  • 3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market
  • Chipscreen Biosciences’ CS08399 Wins NMPA Approval – PRMT5-MTA Inhibitor Targets MTAP-Deficient Solid Tumors and Lymphomas
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Ab&B Bio-Tech Partners with Walvax for Overseas Push – First China-Approved Trivalent Subunit Influenza Vaccine Targets Global Markets

Company Drug

CMS Secures NMPA Approval for Desidustat – First Domestic HIF-PHI for Non-Dialysis CKD Anemia Enters China Market

Company Drug

Hengrui’s Irinotecan Liposome (II) Wins NMPA Phase II Approval – Adjuvant Pancreatic Cancer Study vs. Gemcitabine/Capecitabine

Company Drug

3SBio Wins NMPA Approval for Eltrombopag Generic – TPO-RA Copycat Targets Novartis’ Revolade in China ITP/SAA Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.